Literature DB >> 25261211

Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis.

Hendrik Müller1, Sonja Laier, Andreas Bechdolf.   

Abstract

The aim of psychotherapy among individuals at clinical high risk (CHR) for psychosis is to prevent transition to full-blown psychosis. Psychotherapy in individuals with a first-episode psychosis (FEP) aims to reduce relapse rates. Remission of (pre-) psychotic symptoms, psychosocial functioning, quality of life, comorbid disorders and self-esteem are also important outcomes in individuals at CHR and with FEP. Antipsychotics, Qmega-3-Fatty acids and psychotherapy have been found to be effective in CHR for most of these aims. Thereby psychotherapy presents a better benefit/risk ratio than antipsychotic medication. The most evidence-based intervention is cognitive-behavioral therapy (CBT). Psychotherapy is mostly offered to FEP patients within specialized early intervention services (including assertiveness community treatment and antipsychotic medication). Thereby, CBT is effective for positive symptoms and family intervention is particularly effective for the prevention of relapses. We introduce the principles of CBT for psychosis and suggest adaptions for individuals at CHR and FEP. We conclude that the needs of young people at CHR and with FEP are best met by specially designed, low threshold outpatient clinical services, which include intensive psychotherapy treatment. A number of countries have implemented early detection and intervention services based on this model, while the implementation within in Germany is still marginal.

Entities:  

Mesh:

Year:  2014        PMID: 25261211     DOI: 10.1007/s00406-014-0538-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  85 in total

1.  A cognitive model of the positive symptoms of psychosis.

Authors:  P A Garety; E Kuipers; D Fowler; D Freeman; P E Bebbington
Journal:  Psychol Med       Date:  2001-02       Impact factor: 7.723

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Authors:  Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

4.  Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.

Authors:  P Fusar-Poli; J M Stone; M R Broome; I Valli; A Mechelli; M A McLean; D J Lythgoe; R L O'Gorman; G J Barker; P K McGuire
Journal:  Arch Gen Psychiatry       Date:  2011-05-02

5.  A risk factor screening and assessment protocol for schizophrenia and related psychosis.

Authors:  V Carr; S Halpin; N Lau; S O'Brien; J Beckmann; T Lewin
Journal:  Aust N Z J Psychiatry       Date:  2000-11       Impact factor: 5.744

6.  Diagnosing schizophrenia in the initial prodromal phase.

Authors:  J Klosterkötter; M Hellmich; E M Steinmeyer; F Schultze-Lutter
Journal:  Arch Gen Psychiatry       Date:  2001-02

7.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

8.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

Authors:  Patrick D McGorry; Barnaby Nelson; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Annette Thampi; Gregor E Berger; G Paul Amminger; Magenta B Simmons; Daniel Kelly; Grad Dip; Andrew D Thompson; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

9.  Attitude towards adherence in patients with schizophrenia at discharge.

Authors:  Rebecca Schennach-Wolff; Markus Jäger; Florian Seemüller; Michael Obermeier; Thomas Messer; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Hans-Jürgen Möller; Michael Riedel
Journal:  J Psychiatr Res       Date:  2009-06-07       Impact factor: 4.791

10.  First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences.

Authors:  H Häfner; A Riecher-Rössler; K Maurer; B Fätkenheuer; W Löffler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

View more
  1 in total

1.  Pathways to care, DUP, and types of interventions over 5 years following psychosis onset: findings from a naturalistic study conducted in routine generalist mental health services.

Authors:  Elisabetta Miglietta; Antonio Lasalvia; Chiara Bonetto; Carla Comacchio; Doriana Cristofalo; Sarah Tosato; Katia De Santi; Sara Petterlini; Gioia Zanatta; Carla Cremonese; Luana Ramon; Mirella Ruggeri
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-09-11       Impact factor: 4.328

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.